Understanding how T cells and heart cells talk in a life-threatening heart inflammation from cancer immunotherapy
Official title: Deciphering interactions between human T cells and cardiomyocytes in immune checkpoint inhibitor-related myocarditis
Funded at Massachusetts General Hospital · NIH-11377701 · Data updated 2026-11-12
A doctor–scientist will study how immune T cells interact with heart cells in people treated for cancer who develop dangerous inflammation from immune checkpoint inhibitors.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $197,640 |
| NIH project number | 5K08AI197864-02 |
| Project ID | NIH-11377701 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with cancer who are treated with immune checkpoint inhibitors and at risk for or who have developed irMyocarditis.
✕Less likely to help
Patients without irAEs or those not receiving checkpoint inhibitors may not directly benefit.
What this research studies
This project uses patient samples and human cell models to uncover what drives irMyocarditis, with a plan to map the specific T cells involved and how they affect heart cells. It aims to identify heart-damaging interactions and test ways to block them without reducing anti-cancer effects. The work progresses through three aims: find cardiomyocyte-reactive T cells, reveal harmful interactions between T cells and other heart cells, and test potential strategies to modulate these interactions. By linking patient biology to targeted interventions, the study seeks to pave the way for safer immunotherapy. Strong collaboration between clinicians and researchers at a major cancer center underpins the approach.
Why it matters
Potential benefit: If successful, the research could lead to safer cancer immunotherapies by preventing or treating irMyocarditis.
How similar studies have gone: Prior work shows T-cell involvement in irAEs, but this project aims to define specific cardiac-directed T-cell mechanisms and targeted therapies.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Blum, Steven — Massachusetts General Hospital
- Study coordinator: Blum, Steven
Related research
Other NIH-funded projects on the same topics.
-
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor–Associated Heart Inflammation
A doctor-scientist team is studying why cancer patients treated with immune checkpoint drugs sometimes develop dangerous heart inflammation and what immune targets cause it.
-
Understanding heart inflammation caused by cancer immunotherapy
This study is looking at how certain cancer treatments can sometimes cause heart inflammation called myocarditis, and it's for patients who are receiving these immunotherapy drugs; the researchers want to understand how this happens so they can help improve care for those affected.
-
Understanding how T-cells cause heart inflammation from cancer treatments
This study is looking into how certain cancer treatments can sometimes cause heart inflammation, and it aims to understand how specific immune cells might be causing this issue, so we can find better ways to protect the heart for patients undergoing these therapies.
-
Rapid bedside molecular imaging of heart inflammation with ultrasound
A fast, point-of-care ultrasound test using special contrast bubbles may help doctors quickly see active heart inflammation in people with chest pain or suspected ACS.
-
Muscle-Related Enzyme TRIM55 and Autoimmune Heart Inflammation in Aicardi-Goutieres Syndrome
A new research project studies how a muscle-specific enzyme called TRIM55 drives autoimmune heart inflammation in a genetic syndrome.
-
Targeted CXCR3 blockade to treat immunotherapy-related heart inflammation
A targeted drug approach aims to prevent or lessen heart inflammation caused by immune therapies in cancer patients, using CXCR3-blocking strategies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.